Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies
Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL ·
Trial Information
Current as of September 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new treatment called repetitive transcranial alternating current stimulation (rtACS) to help people with glaucoma, a condition that can damage the eye and affect vision. The study aims to see if this gentle electrical stimulation can help activate certain cells in the eye that are not working well, potentially improving both the structure of the eye and how well patients can see.
The trial is open to adults between the ages of 65 and 74, regardless of gender. While the study is not yet recruiting participants, those who join can expect to receive repeated sessions of this non-invasive brain stimulation. The goal is to understand if this treatment is safe and helpful for people with glaucoma, offering a possible new way to protect or improve vision.
Gender
ALL
Eligibility criteria
About National Taiwan University Hospital
National Taiwan University Hospital (NTUH) is a leading medical institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a pioneer in medical education and patient care in Taiwan, NTUH integrates cutting-edge technology with comprehensive clinical expertise to facilitate groundbreaking studies across various medical fields. The hospital’s dedicated research team collaborates with local and international partners to enhance the understanding of diseases and improve treatment outcomes. By prioritizing patient safety and ethical standards, NTUH strives to contribute to the global medical community and foster advancements in healthcare practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported